miR-101在胰腺癌组织中的表达以及对胰腺癌细胞ASPC-1增殖的影响

目的 观察miR-101在胰腺癌组织中的表达,探讨其对胰腺癌细胞增殖的影响.方法 采用实时定量PCR方法 检测miR-101在胰腺癌组织、癌旁组织和胰腺癌细胞株ASPC-1中的表达.通过基因重组技术构建miR-101的表达载体peGFPc1-miR-101,应用脂质体将其转染到ASPC-1细胞,荧光显微镜检测转染效率;实时定量PCR检测转染细胞miR-101的表达水平,以癌旁正常胰腺组织为1,折算成相对倍数;MTT法检测转染细胞的增殖率.利用在线软件targetScan预测miRNA可能的靶基因.结果 miR-101在胰腺癌组织和胰腺癌细胞株ASPC-1中相对表达量分别为55%和39%,较癌旁正常胰腺组织显著降低(P＜0.01).peGFPc1-miR-101转染ASPC-1细胞后,miR-101表达增加,为对照组的19.8倍(P＜0.01),癌细胞增殖率明显降低,最低仅为原代细胞的26%(P＜0.01).EZH2基因是miR-101影响胰腺癌细胞增殖活力的可能靶基因.结论胰腺癌组织miR-101低表达,它可能通过抑制EZH2的表达调控细胞的增殖.

The expression of miR-101 in pancreatic cancer and its effect on proliferation of pancreatic cancer cell line ASPC1

Objective To investigate the expression of miR-101 in pancreatic cancer and the effect of down-regulation miR-101 on proliferation of pancreatic cancer cell line ASPC1. Methods Real-time PCR was used to determine the expression of miR-101 in pancreatic cancer, adjacent tissues and pancreatic cancer cell line ASPC-1. The miR-101 over-expression vector (peGFPc1-miR-101) was constructed and was transfected into ASPC-1 cell. Transfection efficiency was measured by fluorescence microscope. The expression of miR101in the transfected cells was detected by real-time PCR. Cell viability analysis was performed by MTT. The targeted genes of miR-101 in pancreatic cancer were scanned by the online targeted gene prediction software (target Scan). Results The expression of miR-101 was in pancreatic cancer tissues, adjacent tissues and ASPC-1 cell line, respectively. The expressions in pancreatic cancer tissues and ASPC-1 cells were significantly lower than that in adjacent tissues ( P ＜ 0.01 ). The expression of miR 101 in transfected cells increased to 19.8 folds as much as that in the control group (P ＜0.01 ). Proliferation rate of transfected cells was significantly decreased, which was only 26% of primary cells ( P ＜ 0.01 ). EZH2 was the potential targeted gene of miR-101 in pancreatic cancer. Conclusions miR-101 was weakly expressed and it may affect the proliferation of pancreatic cancer cell by inhibiting the EZH2 expression.